Highlights
About
Anticancer and Stem Cell Mobilization Drugs
Biokine Therapeutics is a clinical-stage biopharmaceutical company developing novel drugs to treat cancer. Founded in 2000 by Prof. Amnon Peled, a leading cancer and stem cell biologist at Hadassah University Hospital, Biokine has completed many years of R&D and clinical research. The company is devoted to identifying novel molecular and cellular mechanisms that regulate tumor development and metastasis. Biokine has developed a suite of unique approaches to target cancer and is conducting preclinical and clinical research on several molecules discovered and developed in-house. The companys lead drug candidate, the high-affinity CXCR4 antagonist BKT140/BL8040, is currently in a phase 2a clinical trial for the treatment of refractory and relapsed acute myeloid leukemia (AML), as well as a phase 1 clinical trial for the mobilization of stem cells. The CXCR4 receptor plays a pivotal role in the regulation of certain cancers and inflammatory diseases and is critically involved in stem cell biology and tissue regeneration. BKT140/BL8040 was licensed to BioLineRx Ltd.
Identity
| Name | Biokine Therapeutics |
|---|---|
| Slug | biokine-therapeutics |
| Type / kind | startup |
| Crunchbase ID | biokine-therapeutics |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgN6OiYIKDA |
Status
| Status | active |
|---|---|
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ region/district | Center District |
| HQ city | Rehovot |
| HQ address | Rehovot, Israel |
Web & social
| Website | https://biokine.com |
|---|---|
| https://www.linkedin.com/company/5550255 |
Classifications
Funding
| Total raised | $1.9M |
|---|---|
| Current stage | Mature |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}